Skip to main content
. Author manuscript; available in PMC: 2007 Dec 3.
Published in final edited form as: Gastroenterology. 2006 Sep;131(3):900–910. doi: 10.1053/j.gastro.2006.06.021

Figure 4.

Figure 4

The effect of the CNS-penetrant opioid antagonist naloxone on pancreatic cancer pain-related behaviors. (A) Spontaneous hunching behavior first became evident in ET mice at approximately 14 weeks (wks), increased in severity until euthanasia and was rarely observed in WT mice at any timepoint examined (n≥8 WT, n≥8 ET). (B) When ET mice were administered the opioid antagonist, naloxone (3 mg/kg, s.c), the hunching behavior became evident at 9-12 wks, increased dramatically at 14-24 wks and was significantly different from WT controls that also received naloxone (n≥8 WT, n≥8 ET). (C) Spontaneous vocalization behavior first became slightly evident in ET mice at approximately 12 wks, increased at 14-24 wks and was observed minimally in WT mice (n≥5 WT, n≥5 ET). (D) The number of vocalization events over a one minute observation period increased at 9-12 wks and 14-24 wks in ET mice following injection of naloxone when compared to age-matched WT mice that also received naloxone (n≥5 WT, n≥5 ET). All error bars shown in A-D represent S.E.M. *p<0.05 vs. WT.